Metoprololsuccinat 1 A Pharma

Active Ingredient:: Metoprolol Succinate
Origin:: EU

Metoprololsuccinat 1 A Pharma (Metoprolol Succinate)

Q: What conditions is Metoprololsuccinat 1 A Pharma used for?

Metoprololsuccinat 1 A Pharma contains metoprolol succinate, a selective β1‑blocker indicated for hypertension, angina pectoris, chronic heart failure, and secondary prevention after myocardial infarction. It helps control blood pressure, reduce chest‑pain episodes, improve heart‑failure symptoms, and lower the risk of further cardiac events.

Q: How does metoprolol succinate work in the body?

Metoprolol succinate blocks β1‑adrenergic receptors primarily in the heart, decreasing the effects of adrenaline and noradrenaline. This reduces heart rate, contractility, and renin release, leading to lower cardiac output and systemic vascular resistance, which together lower blood pressure and myocardial oxygen demand.

Q: What is the usual dose of Metoprololsuccinat 1 A Pharma?

The dose of Metoprololsuccinat 1 A Pharma is individualized by the prescribing clinician based on the patient’s condition, response, and tolerance. Dosage adjustments may be needed for renal or hepatic impairment, and the medication is typically titrated to achieve target blood‑pressure or heart‑failure goals.

Q: Is Metoprololsuccinat safe during pregnancy or breastfeeding?

The pregnancy category for metoprolol succinate is listed as unknown. It should only be used during pregnancy or lactation if the potential benefit outweighs any possible risk to the fetus or infant. Clinicians should discuss risks and alternatives with the patient before prescribing.

Q: How do I order Metoprololsuccinat 1 A Pharma from GNH India?

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Q: How does metoprolol succinate compare with other beta blockers?

Metoprolol succinate is a cardio‑selective (β1‑specific) blocker, offering a lower risk of bronchospasm compared with non‑selective agents like propranolol. Its extended‑release formulation provides once‑daily dosing, which can improve adherence relative to short‑acting beta blockers that require multiple daily doses.

Q: What are the recommended storage conditions for Metoprololsuccinat 1 A Pharma?

Store the tablets at ambient temperature, preferably below 25 °C. Keep them in the original blister pack or container, protect from moisture, heat and direct sunlight. Do not refrigerate or freeze the product.

Q: How is Metoprololsuccinat 1 A Pharma administered?

Metoprololsuccinat 1 A Pharma is taken orally, usually once daily with or without food, as directed by the prescriber. The tablets should be swallowed whole with a full glass of water and not chewed or crushed unless specifically instructed.

Q: What are the most serious risks associated with metoprolol succinate?

Serious adverse events can include severe bradycardia, heart block, hypotension, acute heart‑failure exacerbation, and bronchospasm in susceptible individuals. Patients should be monitored for signs of these conditions, especially during dose initiation or escalation.

Q: Who should not use Metoprololsuccinat 1 A Pharma?

Metoprololsuccinat should be avoided in patients with known hypersensitivity to metoprolol or any excipients, those with severe bradycardia, second‑ or third‑degree AV block without a pacemaker, cardiogenic shock, or uncontrolled asthma. Caution is also advised for patients with severe hepatic impairment.

Metoprolol succinate, the active ingredient in Metoprololsuccinat 1 A Pharma, is a beta blocker presented as an oral tablet for oral use. It is used to lower blood pressure, relieve angina and improve outcomes in chronic heart failure and after myocardial infarction.
GNH India supplies Metoprololsuccinat 1 A Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

1 A Pharma Gmbh

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Metoprolol succinate is a selective β1‑adrenergic blocker indicated for several cardiovascular conditions.

Hypertension: reduces systolic and diastolic pressure by decreasing cardiac output.
Angina pectoris: lessens myocardial oxygen demand, relieving chest pain.
Chronic heart failure: improves ventricular function and reduces hospitalisation risk.
Post‑myocardial infarction: lowers the chance of recurrent ischemic events and mortality.

How It Works

Metoprolol succinate selectively antagonises β1‑adrenergic receptors in cardiac tissue, inhibiting catecholamine‑induced stimulation of adenylate cyclase. This reduces intracellular cyclic AMP, leading to decreased heart rate, myocardial contractility, and renin release, which together lower cardiac output and systemic vascular resistance, thereby lowering blood pressure and myocardial oxygen consumption.

Side Effects

Metoprolol succinate may cause a range of adverse reactions, from mild to severe.

Common Side Effects

Fatigue: feeling of tiredness or reduced energy.
Dizziness: light‑headed sensation, especially on standing.
Bradycardia: slower than normal heart rate.
Cold extremities: reduced peripheral circulation.
Gastrointestinal upset: nausea or abdominal discomfort.

Serious or Rare Side Effects

Severe bradycardia: heart rate <40 bpm requiring medical attention.
Heart block: impairment of electrical conduction.
Acute heart failure exacerbation.
Bronchospasm: difficulty breathing, especially in patients with asthma.
Hypotension: markedly low blood pressure causing faintness.

Precautions & Warnings

Before initiating therapy, clinicians should assess patient‑specific factors and monitor for adverse events.

Cardiovascular assessment: evaluate heart rate, blood pressure and cardiac function.
Respiratory status: avoid use in patients with active bronchospastic disease.
Diabetes monitoring: watch for masking of hypoglycaemia symptoms.
Liver or renal impairment: dose adjustment may be required.
Pregnancy and lactation: use only if potential benefit justifies potential risk; category unknown.
Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and light.

Avoid Interactions

Metoprolol succinate can interact with several drug classes, altering its efficacy or safety profile.

Major Interactions (Avoid)

Non‑selective β‑blockers: additive bradycardia and hypotension.
Calcium channel blockers (verapamil, diltiazem): profound heart‑rate slowing and AV‑block.
CYP2D6 inhibitors (e.g., fluoxetine, quinidine): markedly increased metoprolol plasma levels.

Moderate Interactions (Monitor Closely)

Antidiabetic agents: may mask hypoglycaemia signs.
NSAIDs: can blunt antihypertensive effect.
Diuretics: risk of excessive blood‑pressure reduction.
Antidepressants (tricyclics): may increase bradycardia risk.

Frequently Asked Questions

Metoprololsuccinat 1 A Pharma contains metoprolol succinate, a selective β1‑blocker indicated for hypertension, angina pectoris, chronic heart failure, and secondary prevention after myocardial infarction. It helps control blood pressure, reduce chest‑pain episodes, improve heart‑failure symptoms, and lower the risk of further cardiac events.

Metoprolol succinate blocks β1‑adrenergic receptors primarily in the heart, decreasing the effects of adrenaline and noradrenaline. This reduces heart rate, contractility, and renin release, leading to lower cardiac output and systemic vascular resistance, which together lower blood pressure and myocardial oxygen demand.

The dose of Metoprololsuccinat 1 A Pharma is individualized by the prescribing clinician based on the patient’s condition, response, and tolerance. Dosage adjustments may be needed for renal or hepatic impairment, and the medication is typically titrated to achieve target blood‑pressure or heart‑failure goals.

The pregnancy category for metoprolol succinate is listed as unknown. It should only be used during pregnancy or lactation if the potential benefit outweighs any possible risk to the fetus or infant. Clinicians should discuss risks and alternatives with the patient before prescribing.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Metoprolol succinate is a cardio‑selective (β1‑specific) blocker, offering a lower risk of bronchospasm compared with non‑selective agents like propranolol. Its extended‑release formulation provides once‑daily dosing, which can improve adherence relative to short‑acting beta blockers that require multiple daily doses.

Store the tablets at ambient temperature, preferably below 25 °C. Keep them in the original blister pack or container, protect from moisture, heat and direct sunlight. Do not refrigerate or freeze the product.

Metoprololsuccinat 1 A Pharma is taken orally, usually once daily with or without food, as directed by the prescriber. The tablets should be swallowed whole with a full glass of water and not chewed or crushed unless specifically instructed.

Serious adverse events can include severe bradycardia, heart block, hypotension, acute heart‑failure exacerbation, and bronchospasm in susceptible individuals. Patients should be monitored for signs of these conditions, especially during dose initiation or escalation.

Metoprololsuccinat should be avoided in patients with known hypersensitivity to metoprolol or any excipients, those with severe bradycardia, second‑ or third‑degree AV block without a pacemaker, cardiogenic shock, or uncontrolled asthma. Caution is also advised for patients with severe hepatic impairment.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 08 Sep 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.